Patent Office Opposes Ruling On Ovarian Cancer Drug, Wants Stronger Obviousness Standard

 
• By Brenda Sandburg
  
Ovarian cancer
USPTO is opposed to issuing patent on method of dosing ImmunoGen's ovarian cancer drug • Source: Shutterstock

More from Legal & IP

More from Pink Sheet